Switching to long-acting anti-retroviral therapy with no baseline resistance data: is there value in proviral DNA sequencing? A single-centre pilot study
- 18 June 2026
- journal article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (10) , 1106-1107
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation PeriodInfectious Diseases and Therapy, 2025
- Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIVViruses, 2024
- BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022HIV Medicine, 2022
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006